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Exogenous Control of the Estrous
Cycle in the Mare
Steven K. Puderbaugh, BS, DVM*
Richard L. Riese, DVM* *
The control of estrus, and more importantly
ovulation, may be desirable in a breeding pro-
gram to service an animal at a predetermined
time, to synchronize ovulation in a group of
mares, or to spread ovulations over a pro-
longed period of time according to the various
needs of managing the breeding animals.
Ideally, the goal would be to control ovulation
with enough precision that breeding could be
done without the necessity of estrus detection. 1
Three methods of control (or combination
thereof) can be used: 1) induction of ovulation
during estrus, 2) prolongation of the luteal
phase by administration of a progestin, and 3)
termination of the luteal phase by administra-
tion of Prostaglandin F2a (PGF2a) or one of its
analogues. A point to be remembered is that in
order to allow any useful control over ovulation
time, mares must be either cyclic or so near the
first ovulation of the season as to be considered
cyclic. 2,3 It also should be kept in mind that all
of the following methods and techniques should
be used in conjunction with a good palpation
and teasing program.
INDUCTION OF OVULATION
Ovulation induction techniques are widely
used in the equine industry due to the long and
variable length of estrus. This is intertwined
with the highly variable interval from onset of
estrus to ovulation. Inducing ovulation shows
benefits in improving breeding efficiency in
that the number of breedings can be limited per
conception. The advantages of conserving a
heavily used stallion and decreasing the num-
ber of chances of bacterial contamination and
injury are easily seen.
*Dr. Puderbaugh is a 1983 graduate of the College of
Veterinary Medicine at Iowa State University.
**Dr. Riese is an assistant professor in Veterinary
Clinical Sciences at Iowa State University.
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Three types of hormonal preparations are
available for induction of ovulation. These are
human chorionic gonadotrophin (RCG),a an-
terior pituitary extracts, and gonadotrophic re-
leasing hormones (GnRR).
The hormone RCG has predominantly lu-
teinizing hormone (LR) activity. The dosage
recommended varies from 1500-3000 IU, and
when administered 1M gives consistent re-
sultS. 4,5,6 A study done by Russian workers has
shown a distinct reduction in conception rates
post-treatment when using higher dosages than
3000 IV. 7 The ability of RCG to be antigenic
has the potential to cause an immune reaction.
Some controversy has existed over the capabil-
ity of anti-RCG antibodies to cause neutraliza-
tion of the RCG and ovulatory refractoriness. 8,9
A recent studylO has shown a significant antibo-
dy titer can be produced following repeated in-
jections over a breeding season but that no ovu-
latory refractoriness was noted. Anaphylactic
reactions are possible but are reported to be
rare. 4 Unused portions of the RCG may be
refrigerated or frozen but should be used within
30 days or discarded.
Anterior pituitary extracts are also being
used in ovulation induction. These products
are isolated from the pituitaries of horses or
other species. Pituitary extracts give erratic re-
sults compared to RCG in the horse, and have
the disadvantage of required freezing of the un-
used portion to maintain potency.4,11 The pi-
tuitary extracts do have the ability to induce
follicular growth and multiple ovulations
during the ovulatory season. 1The ability of pi-
tuitary extracts to cause superovulation may
bring increased use as embryo transfer tech-
niques are perfected in the mare. 12
Finally, the gonadotrophic releasing hormone
(GnRR) is being used in ovulation induction.
aChorisol T. M., Burns-Biotec, Omaha, NE 68127.
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GnRH causes release of endogenous LH from
the anterior pituitary and appears to be as effi-
cacious as HCG but without the problems with
antigenicity. Daily administration of 2 mg be-
ginning on the second day of estrus shortens
the duration of estrus and time interval before
ovulation significantly.14 Lengths of the estrus
period averaged 11.8 ± 2.1 days in control and
6.9 ± 0.9 days in treated mares. In the group
of treated mares, 67 % ovulated within 24
hours of GnRH treatment. As of this time,
however, GnRH might often be cost prohibi-
tive since a 2 mg dose now costs about $140.00.
Candidates for induction of ovulation fall in-
to two categories. 4 First ,are those mares bred
during the seasonal ovulatory period at the op-
timal time of their estrous cycle but fail to ovu-
late within 48 hours (of in~emination). These
mares are clinically normal but may have vari-
able estrus lengths due to individual idiosyncra-
sies. Managen1ent errors are a factor due to
poor teasing methods and interpretation.
These mares have a history of annual foaling
but need multiple breedings per conception.
The second group of mares are those which are
bred during the transitional phase of their cy-
cle, especially early in the year. These have a
history of being barren mares with which at-
tempts are made at an early conception. These
transitional mares often show strong signs of
estrus, but insufficient LH release from the pi-
tuitary impedes ovulation.
The mare should be given a complete exam
before undertaking induction of ovulation.4
Each mare should meet the following criteria:
1) There should be a palpable follicle, usually
30-80 mm in diameter. 2) The uterine horns
should be symmetrical and have an edematous
consistency along with the borders of the cervix
being short and indistinct due to relaxation. A
negative culture and biopsy should be obtained
before any breeding attempts when uterine in-
fection is a potential problem, or when the his-
tory indicates their use.
Before use of HCG to induce ovulation, care-
ful consideration must be given to all present
follicles. The extra LH stimulation may result
in multiple ovulations and in increased chance
of twinning. 5 Alternatives are available when
faced with multiple follicles. 4 If there is no
hurry to get the mare bred, it would be best to
Twait until only one mature follicle is present.
Some mares can have a "split" ovulation in
which one follicle ovulates several hours prior
to the other. In this case breeding should be
Vol. 45) No.2
attempted 12 hours after the first ovulation.
This will hopefully allow the first ovum to de-
generate while the second is still viable. The
other option is to go ahead and breed after
ovulation induction since clinical ovulations ex-
ceed the actual number of twin pregnancies
even though both follicles may rupture simulta-
neously. Mares which are covered in spite of
having multiple ovulations should be checked
at 30 days of gestation and proceed to abort the
mare if twin fetuses are present.
PROGESTOGEN TREATMENT
The use of progestins as sychronizing agents
has been found to be effective in the mare. Un-
like some other species, conception rates are
not reduced. Treatment with progesterone-like
compounds has the advantage of not being af-
fected by the stage of cycle at the onset of treat-
ment as in prostaglandin therapy. 15
Several regimens have been used to control
estrus. The most common utilizes a progesto-
gen alone via daily injections for 18 or 19
days.16 Estrus will occur several days after with-
drawal of progesterone. Ovulation can further
be synchronized by administration of HCG six
days post-treatment. 1 Loy et al. 17 has reported
the use of daily injections of 150 mg proges-
terone and 10 mg estradiol-17B for 10 days
along with prostaglandin on the last day of ste-
roid treatment resulting in synchronization of
estrus and ovulation in normally cycling mares.
More variability again occurs when used
during the transition period unless the mares
have been adequately stimulated by an artifi-
cially increased photoperiod prior to beginning
of treatment. 16
An oral progestin, altrenogest, b has been
evaluated in normally cycling mares. 18 A do-
sage of 0.044 mg/kg suspended in neobee oil
appeared to provide the most consistent re-
sponse and is therefore the recommended dose
for broodmares. This dosage is administered
once daily for 15 days. The results with this
dosage were an interval to estrus of 5.0 ± 2.4
days and an interval to ovulation of 10.2 ±3.6
days. Conclusions from several studies have
shown altrenogest to be an effective tool for
minimizing the need for estrus detection and
for synchronization of estrus in normally cy-
cling mares. 15 Mares in estrus at the onset of
bRegumate, American Hoechst Corp., Somerville, NJ
08876.
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treatment will cease to exhibit estrus within 2-
3 days and will continue to be in quiescence for
the duration of treatment. Other products such
as norgestomet implants have been used with
similar' results.
The transition period in the early part of the
breeding season is quite often represented by
irregular estrus periods. Disruption of this ir-
regularity can be accomplished with intramus-
cular treatments with 100 mg per day of pro-
gesterone in oil for seven days.19 Van Niekerk et
al. 20 reported that behavioral estrus was blocked
within two days following treatment initiation
and that most mares were in an ovulatory es-
trus within 3 days after the last treatment.
Mares not in estrus but with active ovaries re-
sponded similarly while those without abun-
dant follicular activity gave poor results.
More recent work has been done using al-
trenogest to assist transitional mares in estab-
lishing normal cycles. 21,22 In one study where 18
mares which had not exhibited a normal es-
trous cycle were treated with altrenogest for 12
days, the duration of post-treatn1ent estrus, in-
terval from the end of treatment to ovulation,
and interval from the first day of estrus to ovu-
1ation were shorter for treated mares than for
control mares. 3 It was also noted that none of
the treated mares experienced split estrual pe-
riods, whereas 6 of 9 control mares did.
Several field trials were also done on the use
of altrenogest using 440 broodmares at 17 dif-
ferent locations. 23 Results of these field trials
have shown altrenogest to be ineffective during
the early transition period, but did show short-
er post-treatment estrus when used during the
late transition period (7.7 days for treated
mares vs. 12.1 days for controls). The interval
to conception was also less (P < .5) for treated
mares than control mares (28 days vs. 41 days
for controls). These results give further evi-
dence of the ability of altrenogest to both sup-
press estrus as well as assist mares in normaliz-
ing their estrous cycles.
Progestogens are often used for suppression
of estrus in mares used for racing, showing or
other events. Daily 1M injections of 50 mg pro-
gesterone in oil beginning prior to the onset of
estrus prevents estrus behavior but not ovula-
tion, while 100 mg per day of progesterone is
needed to block estrus in a normal, cycling
mare if she is in estrus at the start of treatment.
The dosage of 50 to 100 mg per day is adequate
when the mare is showing estrus during the
transitional or anovulatory season. 19 Studies
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have also been done using altrenogest for sup-
pression of estrus. 15 A dosage of 0.44 mg/kg
daily proved to be effective and safe for ex-
tended periods and did not affect subsequent
fertility.
PROSTAGLANDIN-INDUCED
LUTEOLYSIS
Prostaglandin F2a along with a variety of ana-
10gues have shown to be effective luteolytic
agents in the mare. The prostaglandins have
become valuable therapeutic tools to the equine
practitioner as luteolytic agents, both in ter-
minating diestrus and in inducing an early
abortion. Indications for the use of prostaglan-
dins for inducing luteolysis include interrupt-
ing prolonged diestrus due to a spontaneous
persistent corpus luteum (CL), interrupting
prolonged diestrus when diestral ovulation pre-
vents normal return to estrus, changing the dis-
tribution of estrus in groups of mares booked
for breeding to the same stallion to avoid over-
breeding, shortening the interovulatory inter-
val when breeding is passed or missed, shorten-
ing the interovulatory interval when diagnostic
or therapeutic procedures require cervical re-
laxation, synchronizing estrus in donor and re-
cipient mares in preparation for embryo trans-
fer, terminating pregnancy at up to 38 days of
gestation, treatment of mismating, and treat-
ment of those cases of pyometra in which a CL
yersists. 5
Prolonged diestrus is a common cyclic abnor-
mality which must be recognized and dealt
with. It is due to persistence of a CL and is seen
as failure to return to estrus on schedule. Per-
sistent C L may occur spontaneously, in associa-
tion with pyometra or endometrial degenera-
tion, and possibly along with lactation. 25 The
increased life span of the CL is due to lack of
normalluteolysis. Causes of this failure may be
due to lack of prostaglandin (PG), or the pres-
ence of antagonistic endocrine substances at the
time of PG release. Spontaneous persistence of
the CL may last up to 90 days.
Persistence of the CL may also be a result of
uterine changes or pathology that blocks PG
release. 25 Pyometra and endometrial degenera-
tion are the best examples. Pyometra usually
becomes a problem only when the cervix is
closed and fluid persists in the uterine lumen.
Both syndromes inhibit release of PG.
Prolonged diestrus due to early embryonic
death after the formation of endometrial cups
at day 38 should also be mentioned. The endo-
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metrial cups produce pregnant mare serum
gonadotropin (PMSG) which apparently main-
tains luteal function. It isn't clear whether
PMSG prevents luteolysis or induces formation
of new C~s but PMSG is now thought to have
a luteotrophic role. 25 PG luteolysis does not
work as a treatment for prolonged diestrus of
this etiology. Mares will usually not return to
estrus until 100 to 120 days, when the PMSG
production diminishes. No therapeutic regi-
men is available in these cases.
As mentioned before, it is often desirable to
shorten the interovulatory period in a breeding
program via PG luteolysis since the distribu-
tion of intervals from treatment to ovulation is
quite broad. The average time that can be
saved by PG given during diestrus is 1 week. 16
More time can be saved by incorporating
RCG which is usually recommended at 6 days
following PG treatment. 1
In using prostaglandins, it must be under-
stood that a mature CL must be present in
order for luteolysis to occur. This usually trans-
lates to at least 4 days post-ovulation before the
CL is mature and functional and susceptible to
PG Iu teolysis.
Mares are notoriously unpredictable in their
response to prostaglandin-induced luteolysis. 5
The most important factor which controls this
is the follicular status of the ovary at the time of
drug administration. 26 In one study, mares
which had large follicles at the time of treat-
ment showed the most variability in response.
With follicles greater than 40 mm in diameter,
33 % of these follicles regressed and a new folli-
cle ovulated later. In the remainder of the
mares, the large follicle ovulated in shorter
than normal intervals of time following treat-
ment. Some mares ovulated 24-72 hours post-
treatment while showing minimal signs of es-
tru s. 27 Less variability occ1Jrs with smaller
follicles with the average time from treatment
to ovulation being six days.5 If large follicles are
present, daily teasing and palpation to identify
estrus and impending ovulation needs to be
done following prostaglandin treatment.
Other variations in response to prostaglandin
treatment include partial and complete failure
of luteolysis. Results of a study in which a pro-
staglandin analogue was administered in the
presence of a six-day-old CL showed only 65 %
of the mares responded with complete luteolysis
while incomplete luteolysis (where proges-
terone failed to drop to levels which allow es-
trus) occurred 26 % of the time. 28 Recovery of
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the CL following incomplete luteolysis oc-
curred 6 % of the time while no luteolysis oc-
curred 3% of the time.
There are three commercially available pro-
staglandin products that are approved for
equine reproductive work. A natural PGF2a
con1pound, dinoprost trimethamine,c is given
at a dosage of 10~.mg 1M. Prostalened and flu-
prostenole are analogues which are given at do-
sages of 2 mg SC and 250 ug 1M respectively.
A higher number of positive luteolytic re-
sponses are seen when two doses 3:re aqminis-
tered on subsequent days.25
Following dinoprost administration, some
degree of sweating is almost always observed
within 15 - 20 n1inutes of treatn1ent. 25 This can
occasionally be profuse and persistent. Signs of
mild colic or abdominal discomfort may also
appear but last a short time. A posterior ataxia
can also rarely be seen. The PG analogues have
few observable side effects and are chosen more
often to waylay potential client apprehension
than comparative effectiveness of the drugs.
It is important for the reader to understand
that many of the methods of estrous cycle con-
trol which have been discussed were done on an
experimental basis and are not ready to be
widely implemented. The use of RCG and PG
has been well documented and shown to be
quite safe as long as the appropriate dosage and
route of administration are followed. GnRR is
not approved for use in the equine, but altreno-
gest recently received clearance and is available
commercially. A great deal of work is now be-
ing done in these areas and much more will
need to be done in the future.
cProstin, The Upjohn Co., Kalamazoo, MI 49001
dSynchrocept, Diamond Labs, Inc., Des Moines, IA
50303
eEquimate, Haver-Lockhart Labs, Shawnee, KS 66201
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